Condition Focus: Inflammatory Arthropathy — From Mechanisms to Clinical Applications
Published in Current Allergy and Asthma Reports (Springer), this review from Wickenheisser and colleagues bridges the gap between PBM’s cellular mechanisms and its clinical applications in inflammatory, musculoskeletal, and autoimmune disease. While most mechanistic reviews discuss what happens at the cellular level and most clinical reviews report patient outcomes, this paper connects the two — explaining which mechanisms produce which clinical effects in which conditions.
The review covers the inflammatory arthropathies (RA, OA, and related conditions), musculoskeletal pain, and autoimmune disease with joint involvement. It addresses cellular metabolism enhancement, immune cell regulation, and anti-inflammatory signalling as the mechanistic pathways driving clinical improvement.
For gout positioning, this paper provides the conceptual bridge. Gout is classified as an inflammatory crystal arthropathy — it sits squarely within the “inflammatory arthropathy” category covered here. The mechanisms reviewed (anti-inflammatory cytokine modulation, immune cell regulation, cellular metabolism support) are the same mechanisms through which PBM addresses gout pathology. When a clinician asks “where does gout fit in the PBM evidence base?” this paper provides the framework: gout is an inflammatory arthropathy, and PBM has demonstrated efficacy across inflammatory arthropathies through shared mechanistic pathways.
G.O.A.T. for Gout Alignment:
This review positions gout within the broader inflammatory arthropathy evidence framework that PBM addresses. The G.O.A.T. targets gout through the same mechanisms (anti-inflammatory, metabolic, immune-modulatory) that produce clinical benefit across the inflammatory arthropathy spectrum.
Link to original research here
Editor’s note: The inflammatory arthropathy evidence discussed here is supported by the Cochrane RA review in Brosseau et al 2000. The musculoskeletal NSAID comparison is detailed in PBM for MSD 2019. The synoviocyte-specific evidence for RA joints is in Ryu et al 2023. The anti-inflammatory mechanisms underpinning these clinical effects are mapped in Hamblin 2017.
Related Articles
- LLLT for Rheumatoid Arthritis: Cochrane Review – Brosseau et al 2000
- PBM for Musculoskeletal Disorders and OA with NSAID Comparison – 2019
- PBM Ameliorates Inflammatory Parameters in Fibroblast-Like Synoviocytes – Ryu et al 2023
- Anti-Inflammatory Mechanisms of PBM – Hamblin 2017
- Mechanisms and Efficacy of PBM for Arthritis – Zhang et al 2023
Key Takeaways
- Bridges PBM mechanisms to clinical inflammatory arthropathy applications
- Gout fits squarely within the inflammatory arthropathy framework
- Covers anti-inflammatory, metabolic, and immune-modulatory mechanisms
- Published in Current Allergy and Asthma Reports (Springer) — clinical relevance focus
Study Overview
| Study Type: | Review |
| Wavelength(s): | Multiple (red + NIR) |
| Treatment Protocol: | Varies across reviewed studies |
| Sample Size: | Review of inflammatory, MSK, and autoimmune PBM studies |
| Primary Outcome: | Mechanistic-to-clinical bridge for inflammatory arthropathies |
Full Citation
Wickenheisser VA, et al. (2019). Laser light therapy in inflammatory, musculoskeletal, and autoimmune disease. Current Allergy and Asthma Reports, 19(8), 37. View Publication
